ABSTRACT

Introduction

Italy (in pilot regions) and Germany (nationwide) were the first European countries to introduce universal varicella vaccination (UVV) programs.

Areas covered

A systematic review was performed to assess varicella epidemiology before UVV programs and the impact of 1-dose and 2-dose UVV programs in Italy and Germany.

Expert opinion

Italy implemented 1- or 2-dose UVV programs successively in eight pilot regions between 2003 and 2011 and nationwide in 2017. Germany implemented 1- and 2-dose UVV programs in 2004 and 2009, respectively. While Italy had two nationwide surveillance systems in place for varicella in the pre-vaccination era, in Germany, a mandatory notification system for varicella was only introduced in the New Federal States 2 years before the 1-dose UVV implementation. Substantial reductions in moderate/severe varicella and varicella-related hospitalization incidence occurred during the 1-dose era. Further reductions were reported in Italy and Germany after the recommendation of a second dose in a long or short schedule, respectively. Different benefit-risk evaluations of a tetravalent varicella-containing vaccine (MMRV) used as a first dose led to different recommendations (MMRV versus MMR+V) in these countries. Vaccination strategies in both countries tailored to country-specific needs and goals led to a reduction in varicella-related health care hospitalization costs.

中文翻译：

---

意大利和德国的水痘疫苗接种-成功的不同途径：系统评价。

摘要

介绍

意大利（在试点地区）和德国（在全国范围内）是最早引入通用水痘疫苗接种（UVV）计划的欧洲国家。

覆盖区域

在意大利和德国对UVV计划之前的水痘流行病学以及一剂和两剂UVV计划的影响进行了系统的评估。

专家意见

意大利在2003年至2011年以及2017年在八个试点地区相继实施了1剂或2剂UVV计划。德国分别在2004年和2009年实施了1剂或2剂UVV计划。在疫苗接种前的意大利，意大利拥有两个全国性的水痘监测系统，而在德国，仅在实施1剂量UVV的两年前，新的联邦州才引入了水痘的强制性通报系统。在1剂时代，中/重度水痘和住院相关的水痘发病率显着降低。在意大利和德国，分别在长期或短期内推荐第二剂后，据报道进一步减少。在这些国家中，对作为第一剂的四价含水痘疫苗的不同利益风险评估得出了不同的建议（MMRV与MMR + V）。两国的疫苗接种策略均针对特定国家的需求和目标，从而降低了与水痘相关的医疗住院费用。